Display options
Cite
Li CM, Chen J, Lu Y, et al. Pharmacokinetic optimization of 4-substituted methoxybenzoyl-aryl-thiazole and 2-aryl-4-benzoyl-imidazole for improving oral bioavailability. Drug Metab Dispos. 2011;39(10):1833-9doi: 10.1124/dmd.110.036616.
Li, C. M., Chen, J., Lu, Y., Narayanan, R., Parke, D. N., Li, W., Ahn, S., Miller, D. D., & Dalton, J. T. (2011). Pharmacokinetic optimization of 4-substituted methoxybenzoyl-aryl-thiazole and 2-aryl-4-benzoyl-imidazole for improving oral bioavailability. Drug metabolism and disposition: the biological fate of chemicals, 39(10), 1833-9. https://doi.org/10.1124/dmd.110.036616
Li, Chien-Ming, et al. "Pharmacokinetic optimization of 4-substituted methoxybenzoyl-aryl-thiazole and 2-aryl-4-benzoyl-imidazole for improving oral bioavailability." Drug metabolism and disposition: the biological fate of chemicals vol. 39,10 (2011): 1833-9. doi: https://doi.org/10.1124/dmd.110.036616
Li CM, Chen J, Lu Y, Narayanan R, Parke DN, Li W, Ahn S, Miller DD, Dalton JT. Pharmacokinetic optimization of 4-substituted methoxybenzoyl-aryl-thiazole and 2-aryl-4-benzoyl-imidazole for improving oral bioavailability. Drug Metab Dispos. 2011 Oct;39(10):1833-9. doi: 10.1124/dmd.110.036616. Epub 2011 Jul 08. PMID: 21742898; PMCID: PMC3186212.
Copy Download .nbib Format: NLM
Share it on

Drug Metab Dispos. 2011 Oct;39(10):1833-9. doi: 10.1124/dmd.110.036616. Epub 2011 Jul 08.

Pharmacokinetic optimization of 4-substituted methoxybenzoyl-aryl-thiazole and 2-aryl-4-benzoyl-imidazole for improving oral bioavailability.

Drug metabolism and disposition: the biological fate of chemicals

Chien-Ming Li, Jianjun Chen, Yan Lu, Ramesh Narayanan, Deanna N Parke, Wei Li, Sunjoo Ahn, Duane D Miller, James T Dalton

Affiliations

  1. GTx Inc., Memphis, TN, USA.

PMID: 21742898 PMCID: PMC3186212 DOI: 10.1124/dmd.110.036616

Abstract

Microtubules are critical components of the cytoskeleton. Perturbing their function arrests the growth of a broad spectrum of cancer cell lines, making microtubules an excellent and established target for chemotherapy. All of the U.S. Food and Drug Administration-approved antitubulin agents bind to paclitaxel or vinblastine binding sites in tubulin. Because of the complexity of their structures, it is difficult to structurally modify the vinca alkaloids and taxanes and develop orally bioavailable agents. Antitubulin agents that target the colchicine-binding site in tubulin may provide a better opportunity to be developed for oral use because of their relatively simple structures and physicochemical properties. A potent antitubulin agent, 4-(3,4,5-trimethoxybenzoyl)-2-phenyl-thiazole (SMART-H), binding to the colchicine-binding site, was discovered in our laboratory. However, the bioavailability of SMART-H was low because of its poor solubility. Structural modification of SMART-H led to the development of 2-aryl-4-benzoyl-imidazole analog (ABI-274), with improved bioavailability and potency but still considerable first-pass metabolism. A chlorine derivative (ABI-286), replacing the methyl site of ABI-274, resulted in 1.5-fold higher metabolic stability in vitro and 1.8-fold lower clearance in rats in vivo, indicating that metabolic stability of ABI-274 can be extended by blocking benzylic hydroxylation. Overall, ABI-274 and ABI-286 provided 2.4- and 5.5-fold increases in exposure (area under the curve) after oral dosing in rats compared with SMART-H. Most importantly, the structural modifications did not compromise potency. ABI-286 exhibited moderate clearance, moderate volume of distribution, and acceptable oral bioavailability. This study provided the first evidence that ABI-286 may be the first member of a new class of orally bioavailable antitubulin agents.

References

  1. Clin Cancer Res. 2006 May 1;12(9):2834-40 - PubMed
  2. Curr Opin Drug Discov Devel. 2003 Jan;6(1):57-65 - PubMed
  3. Curr Cancer Drug Targets. 2007 Dec;7(8):730-42 - PubMed
  4. J Pharmacol Exp Ther. 2007 Oct;323(1):398-405 - PubMed
  5. Eur J Pharm Sci. 2007 Aug;31(5):249-61 - PubMed
  6. Cancer Res. 1995 Jun 1;55(11):2325-33 - PubMed
  7. Mol Cancer Ther. 2003 Mar;2(3):227-33 - PubMed
  8. Nat Rev Cancer. 2004 Apr;4(4):253-65 - PubMed
  9. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3459-69 - PubMed
  10. J Pharm Biomed Anal. 2006 Jun 16;41(4):1342-6 - PubMed
  11. Nature. 1998 Jan 8;391(6663):199-203 - PubMed
  12. J Med Chem. 2002 Jul 4;45(14):3143-60 - PubMed
  13. Drug Metab Dispos. 2010 Nov;38(11):2032-9 - PubMed
  14. Pharmacol Rep. 2006 May-Jun;58(3):341-52 - PubMed
  15. Mol Cancer Ther. 2003 Sep;2(9):873-84 - PubMed
  16. Br J Cancer. 2010 Apr 27;102(9):1355-60 - PubMed
  17. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4096-100 - PubMed
  18. Cancer Res. 2011 Jan 1;71(1):216-24 - PubMed
  19. J Med Chem. 2010 Oct 28;53(20):7414-27 - PubMed
  20. AAPS J. 2009 Jun;11(2):262-76 - PubMed
  21. Cancer Chemother Pharmacol. 1999;43(2):115-25 - PubMed
  22. Pharmacotherapy. 2003 Feb;23(2):165-72 - PubMed
  23. J Med Chem. 2009 Mar 26;52(6):1701-11 - PubMed
  24. Xenobiotica. 1992 Jul;22(7):743-55 - PubMed
  25. Nature. 2005 May 26;435(7041):519-22 - PubMed
  26. J Pharm Pharm Sci. 2008;11(3):97-105 - PubMed

Substances

MeSH terms

Publication Types

Grant support